ArticleScientific reports2017
Resveratrol therapeutics combines both antimicrobial and immunomodulatory properties against respiratory infection by nontypeable Haemophilus influenzae.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- A bacterial pangenome association study identifies a role for polyamine metabolism and alkaline tolerance in middle ear infections.PLoS pathogens · 2026Article
- NF-κB Signaling Pathway in Rheumatoid Arthritis: Mechanisms and Therapeutic Potential.Molecular neurobiology · 2025Review
- Potential of Resveratrol to Combine with Hydrogel for Photodynamic Therapy against Bacteria and Cancer-A Review.Biomedicines · 2024Review
- Exploring the potential role of microbiota and metabolites in acute exacerbation of chronic obstructive pulmonary disease.Frontiers in microbiology · 2024Article
- Review
- Role of Olive Bioactive Compounds in Respiratory Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Regulation of Host Defense Peptide Synthesis by Polyphenols.Antibiotics (Basel, Switzerland) · 2023Review
- Biological function of resveratrol and its application in animal production: a review.Journal of animal science and biotechnology · 2023Review
- Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.Journal of natural products · 2022Review
- Article
- The Ability of Resveratrol to Attenuate Ovalbumin-Mediated Allergic Asthma Is Associated With Changes in Microbiota Involving the Gut-Lung Axis, Enhanced Barrier Function and Decreased Inflammation in the Lungs.Frontiers in immunology · 2022Article
- Resveratrol Can Attenuate Astrocyte Activation to Treat Spinal Cord Injury by Inhibiting Inflammatory Responses.Molecular neurobiology · 2021Review
- Value of refined care in patients with acute exacerbation of chronic obstructive pulmonary disease.World journal of clinical cases · 2021Article
- Chronic infection by nontypeableERJ open research · 2021Article
- Antimicrobial and Anti-Inflammatory Activity of Apple Polyphenol Phloretin on Respiratory Pathogens Associated With Chronic Obstructive Pulmonary Disease.Frontiers in cellular and infection microbiology · 2021Article
- Stilbenoids: A Natural Arsenal against Bacterial Pathogens.Antibiotics (Basel, Switzerland) · 2020Review
- The Functional Medicine Approach to COVID-19: Virus-Specific Nutraceutical and Botanical Agents.Integrative medicine (Encinitas, Calif.) · 2020Review
- Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review.Foods (Basel, Switzerland) · 2020Review
- Preclinical Evaluation of the Antimicrobial-Immunomodulatory Dual Action of Xenohormetic Molecules againstBiomolecules · 2019Article
- Moonlighting of Haemophilus influenzae heme acquisition systems contributes to the host airway-pathogen interplay in a coordinated manner.Virulence · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The respiratory pathogen nontypeable Haemophilus influenzae (NTHi) is an important cause of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) that requires efficient treatments. A previous screening for host genes differentially expressed upon NTHi infection identified sirtuin-1, which encodes a NAD-dependent deacetylase protective against emphysema and is activated by resveratrol. This polyphenol concomitantly reduces NTHi viability, therefore highlighting its therapeutic potential against NTHi infection at the COPD airway. In this study, resveratrol antimicrobial effect on NTHi was shown to be bacteriostatic and did not induce resistance development in vitro. Analysis of modulatory properties on the NTHi-host airway epithelial interplay showed that resveratrol modulates bacterial invasion but not subcellular location, reduces inflammation without targeting phosphodiesterase 4B gene expression, and dampens β defensin-2 gene expression in infected cells. Moreover, resveratrol therapeutics against NTHi was evaluated in vivo on mouse respiratory and zebrafish septicemia infection model systems, showing to decrease NTHi viability in a dose-dependent manner and reduce airway inflammation upon infection, and to have a significant bacterial clearing effect without signs of host toxicity, respectively. This study presents resveratrol as a therapeutic of particular translational significance due to the attractiveness of targeting both infection and overactive inflammation at the COPD airway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.